Study #2018-0872
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
MD Anderson Study Status
Not Accepting
Treatment Agent
Nirogacestat oral tablet, Placebo Oral Tablet
Description
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Desmoid Tumor, Aggressive Fibromatosis
Study phase:
Phase III
Physician name:
Ravin Ratan
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-844-829-9300
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.